Interview with Scailyte’s CEO Peter Nestorov

In an interview on the platform for high-tech startups Venturelab, Peter confirms something that we were already starting to presume in Hemex; Scailyte is developing rapidly. “However, the learning curve has been and still is extremely steep – as the start-up develops rapidly, so do I, and that is really exciting”.

As a founder and CEO, Peter faces a lot of challenges in his daily activities, but he always had the interest to be involved in multiple initiatives. “I managed a student NGO during my studies and organized numerous international meetings, so I had some basis when I decided to become the CEO of a startup”. It is exactly this transition to become the CEO of a company like Scailyte that has given Peter the skills to succeed as an entrepreneur.

The path of an entrepreneur is sometimes harsh. Peter states that surrounding yourself with a smart and experienced team is necessary. “What helps me a lot is the support and coaching I receive from more experienced entrepreneurs and experts from various industries”.

We at Hemex are thrilled to work with vibrant start-ups like Scailyte. Our slogan “Your Ideas. Our Expertise. One Goal.” reflects that we support the start-ups to achieve a common goal, to efficiently combine the smart ideas of entrepreneurs like Peter Nestorov, with our bench-to-market expertise in order to improve patients’ lives.

You can find the full interview here.

Scailyte is a data-driven biomarker discovery company, that detects complex disease patterns from single-cell data at the onset of disease. Only a small fraction of cells is abnormal, and the changes of the molecular profile are subtle. Scailyte’s technology provides unprecedented insights into diseases by uncovering hidden “single-cell” secrets. With an AI-driven approach, Scailyte is unlocking the potential of single-cell data for early diagnostics. Scailyte is ranked among the Top100 Swiss Startups since 2019 and has won the MassChallenge Switzerland in 2018.

Hemex is a privately-owned Swiss investment and consulting company headquartered close to the Basel global life sciences hub, with its focus to bring innovative drugs, medical devices, and in vitro diagnostics to the market. HEMEX specializes in supporting early-stage start-ups, offering tailored solutions to accelerate the project into a successful and sustainable business. Additionally, HEMEX helps start-ups in their efforts to find non-dilutive and dilutive funding.

At Hemex we are proud to have recognized Scailyte’s potential and to be part of their successful journey.

Scailyte is finalist for Nature Research Spinoff Prize!

Congratulations to our portfolio company Scailyte for being selected among the 12 finalists for the Nature Research Spinoff Prize.

The Spinoff Prize is a new Nature Research Award for early-stage university spinoff companies from around the world. The Award has been established by Nature Research in partnership with Merck to showcase and celebrate global excellence in the commercialization of research through the creation of spinoff companies. The Spinoff Prize aims to encourage and provide visibility to academic entrepreneurs and their startups. The judging panel looks for spinoffs that translate original, high-quality scientific research into products and services that address market problems and are well positioned to make a positive impact on society. The focus of this year’s award involves four categories: pharmaceuticals, agriculture, chemicals, and digital technologies. We are particularly proud that Scailyte has reached the finals of this fantastic showcase!

Scailyte is a data-driven biomarker discovery company, that detects complex disease patterns from single-cell data at the onset of disease. Only a small fraction of cells is abnormal, and the changes of the molecular profile are subtle. Scailyte’s technology provides unprecedented insights into diseases by uncovering hidden “single-cell” secrets. With an AI-driven approach, Scailyte is unlocking the potential of single-cell data for early diagnostics. Scailyte is ranked among the Top100 Swiss Startups since 2019 and has won the MassChallenge Switzerland in 2018.

Hemex is a privately-owned swiss investment and consulting company headquartered close to the Basel global life sciences hub, with its focus to bring innovative drugs, medical devices, and in vitro diagnostics to the market. HEMEX specializes in supporting early-stage start-ups, offering tailored solutions to accelerate the project into a successful and sustainable business. Additionally, HEMEX helps start-ups in their efforts to find non-dilutive and dilutive funding.

At Hemex we are proud to have recognized Scailyte’s potential and to be part of their successful journey.

Rapid COVID-19 Diagnostic Test – launched by ender diagnostics!

Swiss-based start-up ender diagnostics develops rapid molecular tests for the detection of SARS-CoV-2. The first rapid test has just been CE -certified and can now be used in laboratories worldwide.

What makes the ender LAB and subsequent ender MAS test outstanding is not just that the result is obtained within 30 minutes, but also that its accuracy is comparable to the current gold standard. The ender team has extensive experience in developing molecular biological rapid tests. 

PR_CE mark for ender LAB_20200615

 

 

HEMEX supports ender’s team with clinical, regulatory and marketing services. HEMEX’s regulatory experts will support with the CE-certification of the test as an in vitro diagnostic medical device under the European In Vitro Diagnostic Regulation (IVDR). 

Swiss Innovation Challenge – 2nd Round!

Numerous Swiss and European start-ups and SME’s applied for this year’s Swiss Innovation Challenge! In the 1st pitching round, 100 innovative participants presented their projects in front of a competent jury.  Selected start-ups also benefit from a comprehensive support platform with individual coaching, tailored education, and mentoring, as well as get access to potential investors and business partners.

Next, 50 ventures move on to the 2nd pitching round in this challenge. Start-ups and SMEs continue to receive expert support to accelerate their innovative projects and face the competition through three elimination rounds in total. In addition to the main award, participants can win special prizes in the fields of “Globalization”, “Life Sciences” and “Construction”.

Within the Life Sciences Start-ups, we are proud to see 3 HEMEX portfolio start-ups!

 

GeneLook logoGeneLook enables patients to actively use their genetic data in a meaningful way by allowing the healthcare ecosystem to utilize their data in order to facilitate discoveries of new treatments. GeneLook strategically focuses on rare disease patients, to further characterize their diseases, and to improve and accelerate the medical treatment journey.

 

Hi-D Imaging logo

Hi-D Imaging is an ETHZ spin-off aiming to revolutionize the cardiovascular sector by making personalized heart valve replacement therapy a reality. Hi-D (pronounced “Heidi”) develops the world’s first AI-based pre-operational planning platform to assess different heart valves for the patient-specific anatomy, and recommends the optimum shape and size of the valve to the surgeon. The start-up’s technology will increase the quality-of-life of the patient, decrease complications, reduce long-term costs, and increase the overall success rate of the surgery.

 

Resistell logoResistell is an EPFL spin-off developing world’s fastest antibiotic susceptibility test in order to help physicians around the world save patients’ lives. Resistell’s solution is needed more than ever due to increasing antimicrobial resistance, emergency of side effects due to potent antibiotics, not the least in the context of global pandemics. Its life-saving technology is based on the detection of movement caused by living bacterial cells and provides information on which antibiotic should be used to treat the patient, and the concentration at which it should be administered

 

HEMEX is a Bench-to-Market Life Science Provider. We support life science start-ups with a wide range of expertise, either in-house or via our network of pre-qualified experts, laboratories, CMOs, warehouses, logistic partners and affiliates. Our development team supports with Quality Assurance, Medical and Regulatory Affairs, Clinical Operations, Biostatistics, Medical Writing and eSubmissions.

 

Rapid Testing For Acute COVID-19

Reliable, fast and cost effective, are the attributes of the new COVID-19 testing kits that will be launched shortly by ender diagnostics ag.

The recently incorporated Swiss start-up ender diagnostics can rely on a skilled and experienced team of scientists and entrepreneurs, developing molecular biological rapid tests for infectious diseases. The ender testing kit provides rapid and reliable results for acute COVID–19. Capable of diagnosing multiple samples at once and within just 30 minutes, their first of 3 products “ender LAB”  can diagnose several hundred samples simoultaneously,  and  will thus reduce the time needed to get a reliable diagnosis significantly.

PR_ender LAB_20200506_EN

 

HEMEX supports the ender team with clinical, regulatory and marketing services. HEMEX’s regulatory experts will support with the CE-certifification of the test as an in vitro diagnostic medical device under the European In Vitro Diagnostic Regulation (IVDR). 

COVID-19 Realtime Tracking App Available in Switzerland and Germany Now

Hand holding mobile with geoHealthApp for COVID-19 tracking

The new GeoHealthApp enables users in Germany and Switzerland to determine their individual infection risk for COVID-19, thus making a pivotal contribution to reduce the spread of SARS-CoV2.

Through a traffic light system on their smartphone display, users receive information about individualized current infection risks. The information results from the frequented locations of the past 14 days as well as personal information related to symptoms. An interactive map shows areas with high infection rates, that can be avoided. The provision of personal data is voluntary and anonymous. No personal data is passed on to any third parties.

After successful launch of the Betaversion some weeks ago, GeoHealthApp today announced the launch of the app that will enable people to protect themselves more quickly and better against pandemic crises, in particular against the current COVID-19 spread.

The app is free of charge in Germany and Switzerland and can be downloaded from the App Store and the Google Play store.

2404_geoHealthApp-Onepager-AJ

 

 

GeoHealthApp received the support from HEMEX, whose regulatory experts helped to register the software as a CE-certified medical device under the European Medical Device Regulation, and also make sure that all data are handled in full compliance with General Data Protection Regulations (GDPR).

Welcome Hi-D Imaging!

Medical technology diagnostics of heart concept.Medicine doctor and stethoscope working with Ui heart and diagnostics analysis medical treatment.

We are delighted to welcome Hi-D Imaging AG to our growing list of portfolio companies and are pleased to support them as a strategic clinical and regulatory development partner.

Hi-D Imaging AG, an ETH Spin-off medtech company founded in July 2019, aims to revolutionize the cardiovascular sector by making personalized aortic heart valve replacement therapy a reality. The diverse team of engineers and cardiologists of Hi-D applies high precision fluid dynamics analysis and machine learning algorithms to develop the world’s first AI-based pre-operational planning platform. The platform assesses full hemodynamics in patient-specific anatomies and is offered as “Software as a Service” (SaaS).  

Hi-D’s goal is to increase the patient’s quality of life and optimize the design of next-generation heart valves. Hi-D builds a bridge between clinical teams and heart valve manufacturers to provide the best treatment for patients with cardiovascular diseases. Hi-D is planning 3 clinical proof of concept trials in Europe and in the US.

The start-ups will share more information on their journey at the HEMEX pitching event on June 5th.

The HEMEX PORTFOLIO contains a selection of the most promising Swiss and European life science start-ups. Headquartered close to the Basel global life sciences hub, our main focus to bring innovative drugs, medical devices and in vitro diagnostics to the market. HEMEX specializes in supporting early-stage start-ups, offering tailored solutions to accelerate the project into a successful and sustainable business.

Annaida Technologies SA Closes CHF 1M Seed Financing Round

Lausanne, 09 April 2020

Annaida Technologies SA today closed an oversubscribed seed financing round led by HEMEX. Zürcher Kantonalbank, Fongit Seed Invest (FSI), Business Angels Switzerland (BAS), Privilège Ventures, Venture Kick and an angel investor also joined the round to support the start-up developing non-invasive embryo screening technology.

Every year more couples turn to In Vitro Fertilization (IVF) when trying to conceive. The unreliability of IVF multiplies costs as more cycles and tests are required, adding to the emotional and physical burden of such procedures. A crucial aspect of the cycle is the choice of the best embryo for transfer, the one with the highest chance of becoming a healthy baby. Current methods, by examination under a microscope or by taking a biopsy of as much as 15 percent of the embryo’s cells, are too qualitative or too slow and invasive, resulting in successful pregnancies 35 percent of the time on average. Doctors need something better.

To improve the IVF process, a non-invasive yet quantitative embryo screening method is highly sought after. EPFL spin-off Annaida is developing the device to achieve it, harnessing a technology that is delicate enough to use on a human embryo. The startup’s device performs microscopic Nuclear Magnetic Resonance (“µNMR”) at a scale 10-fold better than existing technologies. Like an MRI scanner, shrunk to suit embryos about one-fifth of a millimeter in size the device will allow IVF clinics to perform their analysis on-site and within an hour. Fertility is a growing global market, already worth over CHF 20 billion, with patients already spending over 1 billion on screening embryos for viability. Europe’s clinics perform over 700,000 cycles every year, more than any other continent, making it the ideal place to start. Beyond IVF, Annaida’s device can enable other valuable applications in biochemical research and pharmacology. This is only the beginning.

Annaida Technologies SA was incorporated in June 2019 with a first investment by HEMEX and an angel investor. The funds allowed for substantial advancements to the device and the establishment of essential collaborations for future progress. The goal of the current, milestone-based CHF 1M seed round is to validate the device’s safety and to run preclinical trials to define biomarkers for embryo viability.

“In this round we are adding a diverse set of investors which provide a unique mix of relevant expertise, a valuable network, ability to further support Annaida in the future and the stability needed to fully realize our potential. We are fortunate to have investors that share our vision and see beyond the uncertainties of today’s market” said CEO Gora Conley.

“With this support we are now able to push forward our development towards a technology that will have unparalleled performance, high resolving power, and that is safe for use on something as delicate as a human embryo. Annaida will bring µNMR, and the know-how we are developing, to areas where the current solutions simply don’t offer enough” said CTO Marco Grisi.

ABOUT ZÜRCHER KANTONALBANK
Zürcher Kantonalbank is a leading universal bank in the Zurich economic area with Swiss roots and international reach. It is an independent, incorporated public-law institution of the Canton of Zurich and has received top ratings from the rating agencies Standard & Poor’s, Moody’s and Fitch (AAA/Aaa). With more than 5,000 employees, Zürcher Kantonalbank offers its clients a comprehensive range of products and services. The bank’s core activities include financing businesses, asset and wealth management, trading, capital market transactions, deposits, payment transactions and the card business. Zürcher Kantonalbank provides clients and distribution partners with a comprehensive range of investment and retirement provision products and services.

ABOUT HEMEX
HEMEX AG is a privately-owned Swiss investment and consulting company headquartered close to the Basel global life sciences hub, with its main focus to bring innovative drugs, medical devices and in vitro diagnostics to the market. HEMEX specializes in supporting early-stage start-ups, offering tailored solutions to accelerate the project into a successful and sustainable business. Additionally, HEMEX helps start-ups in their efforts to find non-dilutive and dilutive funding. More at https://hemex.eu/

ABOUT FONGIT SEED INVEST (FSI)
Fongit Seed Invest (FSI) is a Geneva based Seed-Money Fund investing in young technology companies since more than 20 years. It provides smart seed capital and it actively assists entrepreneurs to foster, expand and strengthen their venture by leveraging its strong network of partners and experts. FSI focuses in ventures having disruptive, proprietary and patented enabling technologies and solely invests in fully committed teams capable of delivering rapidly unique and innovative products and technology-based solutions. 

ABOUT PRIVILEGE VENTURES
Privilège Ventures invests mainly in Swiss and European seed level companies – often we are the first professional investor on the cap table. We have more than 20 companies in the combined portfolio of Fund I and II. We believe in deeptech driven by compelling entrepreneurs allowing the creation of value for our investors over time. 

ABOUT BUSINESS ANGELS SWITZERLAND
BAS (Business Angels Switzerland), founded in 1997 and the oldest business angels club in the country, supports startup companies through capital financing. BAS members invest their own time and money and have financed more than 150 startups within the framework of the club with a track record of more than 9 Exits. Alone in 2019 over CHF 2,3m were invested in 17 startups, 1st round or follow on rounds. Members also share expertise, know-how and personal contacts with the companies they invest in. 

ABOUT VENTURE KICK
Venture Kick kicks spin-off projects out of Swiss university labs by providing up to CHF 150,000 in seed-money, a global network to investors and hands-on coaching. Venture Kick is organized as a fully private and philanthropic foundation with the goal of fostering job creation, and social and economic prosperity in Switzerland. Since 2007, Venture Kick has invested CHF 30 million in 700 projects, which today represent 519 companies and more than 7,000 jobs. Startups supported by Venture Kick have raised more than CHF 3.5 billion in investments to date. www.venturekick.ch/portfolio  

For further information please contact:
Annaida Technologies SA
Dr. Gora Conley, CEO
info@annaida.ch
+41 78 631 33 53

 

 

Swiss Innovation Challenge – Digital kick-off!

2020 Swiss Innovation Challenge – the traditional networking kick-off event for the SIC was held virtually due to COVID-19 crisis on April 2, 2020!

Numerous entrepreneurs from Switzerland and other European countries attended the online kick-off for this years challenge. 100 start-ups from all categories will be admitted to the first pitch, but only 50 are eligible for the next round. The selection process consists of 3 pitching cycles in total. The whole challenge is supported by a mentoring- and coaching program.

The winners of the SIC will be announced at the award ceremony on November 26th, 2020.

The SIC was launched in 2014 by Baselland Chamber of Commerce, the University of Applied Sciences Northwestern Switzerland (FHNW) and the Bank of Baselland (BLKB).

HEMEX will support this 6th edition with a special prize in the “Life Sciences” category and take place in the jury.

HEMEX is a Bench-to-Market Life Science Provider. We support life science start-ups with a wide range of expertise, either in-house or via our network of pre-qualified experts, laboratories, CMOs, warehouses, logistic partners and affiliates. Our development team supports with Quality Assurance, Medical and Regulatory Affairs, Clinical Operations, Biostatistics, Medical Writing and eSubmissions.